## Background: Prostate-specific antigen (psa) is a good objective measure of tumor cell burden or virulence of disease, or both, in prostate cancer. many differences between whites and african americans (aa) have been noted in prostate cancer in the united states, including a poorer outcome in afr
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma
โ Scribed by Robert S. DiPaola; Eric S. Chenven; Weichung J. Shih; Yong Lin; Peter Amenta; Susan Goodin Pharm.D.; Adam Shumate; Terry Capanna R.N.; Marie Cardiella B.S.; Kenneth B. Cummings; Joseph Aisner; Mary B. Todd D.O.
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 294 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru
## BACKGROUND. To understand better the natural history and biology of prostate carcinoma occurring in Japanese patients, the authors attempted to define changes with time in prostate specific antigen (PSA) measurements in 48 men with clinically resectable T1-T3 nonmetastatic disease. ## METHODS.
## Background: The authors analyzed retrospectively their institution's experience in treating patients with localized prostate carcinoma with external beam radiation therapy (ebrt) to determine the correlation of various biochemical failure (bf) definitions with clinical failure and cause specific